Your browser doesn't support javascript.
loading
Genomic characterization and risk stratification of esophageal squamous dysplasia.
Min, Qingjie; Zhang, Min; Lin, Dongmei; Zhang, Weimin; Li, Xianfeng; Zhao, Lianmei; Teng, Huajing; He, Tao; Sun, Wei; Fan, Jiawen; Yu, Xiying; Chen, Jie; Li, Jinting; Gao, Xiaohan; Dong, Bin; Liu, Rui; Liu, Xuefeng; Song, Yongmei; Cui, Yongping; Lu, Shih-Hsin; Li, Ruiqiang; Guo, Mingzhou; Wang, Yan; Zhan, Qimin.
Affiliation
  • Min Q; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
  • Zhang M; Novogene Co. Ltd, Beijing, China.
  • Lin D; Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China.
  • Zhang W; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
  • Li X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
  • Zhao L; Department of Gastroenterology, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
  • Teng H; Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
  • He T; Department of Radiation Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China.
  • Sun W; Department of Gastroenterology & Hepatology, Chinese PLA General Hospital, Beijing, China.
  • Fan J; Department of Pathology, Characteristic Medical Center of Chinese People's Armed Police Force, Tianjin, China.
  • Yu X; Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China.
  • Chen J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
  • Li J; Department of Etiology and Carcinogenesis and State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Gao X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
  • Dong B; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
  • Liu R; State Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Liu X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Central Laboratory, Peking University Cancer Hospital & Institute, Beijing, China.
  • Song Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
  • Cui Y; Institute of Cancer Stem Cell, Dalian Medical University, Dalian, Liaoning, China.
  • Lu SH; State Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Li R; Shenzhen Peking University-The Hong Kong University of Science and Technology (PKU-HKUST) Medical Center, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
  • Guo M; Department of Etiology and Carcinogenesis and State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Wang Y; Novogene Co. Ltd, Beijing, China.
  • Zhan Q; Department of Gastroenterology & Hepatology, Chinese PLA General Hospital, Beijing, China.
Med Rev (2021) ; 4(3): 244-256, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38919397
ABSTRACT

Objectives:

The majority of esophageal squamous dysplasia (ESD) patients progress slowly, while a subset of patients can undergo recurrence rapidly or progress to invasive cancer even after proper treatment. However, the molecular mechanisms underlying these clinical observations are still largely unknown.

Methods:

By sequencing the genomic data of 160 clinical samples from 49 tumor-free ESD patients and 88 esophageal squamous cell carcinoma (ESCC) patients, we demonstrated lower somatic mutation and copy number alteration (CNA) burden in ESD compared with ESCC.

Results:

Cross-species screening and functional assays identified ACSM5 as a novel driver gene for ESD progression. Furthermore, we revealed that miR-4292 promoted ESD progression and could serve as a non-invasive diagnostic marker for ESD.

Conclusions:

These findings largely expanded our understanding of ESD genetics and tumorigenesis, which possessed promising significance for improving early diagnosis, reducing overtreatment, and identifying high-risk ESD patients.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Med Rev (2021) Year: 2024 Document type: Article Affiliation country: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Med Rev (2021) Year: 2024 Document type: Article Affiliation country: China